This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets. New marketing authorisations Table 1 shows the new marketing authorisations for March 2025 New Marketing Authorisations Product name and target species Active substance Authorisation Holder, territory, and distribution category Therapeutic group Food Animals Censutrim 200 mg/ml + 40 mg/ml Solution for I

New research* published by the University of Melbourne in partnership with the SPILLERSTM brand, is enhancing knowledge about how best to manage horses and ponies with pituitary pars intermedia dysfunction (PPID), ultimately to help to reduce the risk of laminitis. The study shows that pergolide mesylate, the most common drug used to treat PPID, may reduce the amount of insulin produced in response to eating, in horses and ponies that have PPID together with ID. It also suggests that a low sugar

This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists changes to authorisations most relevant to vets. The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed. Changes to the SPC, labels and leaflets may change how the medicines should be used. Details can be found o